IL325858A - Anti-cthrc1 t cell engagers and methods of using the same - Google Patents

Anti-cthrc1 t cell engagers and methods of using the same

Info

Publication number
IL325858A
IL325858A IL325858A IL32585826A IL325858A IL 325858 A IL325858 A IL 325858A IL 325858 A IL325858 A IL 325858A IL 32585826 A IL32585826 A IL 32585826A IL 325858 A IL325858 A IL 325858A
Authority
IL
Israel
Prior art keywords
cthrc1
methods
same
cell engagers
engagers
Prior art date
Application number
IL325858A
Other languages
Hebrew (he)
Inventor
Christopher Harvey
Max London
Michael Briskin
Nikolai Suslov
Original Assignee
Phenomic Ai
Christopher Harvey
Max London
Michael Briskin
Nikolai Suslov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenomic Ai, Christopher Harvey, Max London, Michael Briskin, Nikolai Suslov filed Critical Phenomic Ai
Publication of IL325858A publication Critical patent/IL325858A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
IL325858A 2023-07-12 2024-07-12 Anti-cthrc1 t cell engagers and methods of using the same IL325858A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363526444P 2023-07-12 2023-07-12
PCT/US2024/037940 WO2025015320A2 (en) 2023-07-12 2024-07-12 Anti-cthrc1 t cell engagers and methods of using the same

Publications (1)

Publication Number Publication Date
IL325858A true IL325858A (en) 2026-03-01

Family

ID=94216496

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325858A IL325858A (en) 2023-07-12 2024-07-12 Anti-cthrc1 t cell engagers and methods of using the same

Country Status (3)

Country Link
AU (1) AU2024293963A1 (en)
IL (1) IL325858A (en)
WO (1) WO2025015320A2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2356270T3 (en) * 2008-11-07 2016-12-12 Fabrus Llc Combinatorial antibody libraries and uses thereof
EP2789630A1 (en) * 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
WO2020250204A1 (en) * 2019-06-13 2020-12-17 프레스티지 바이오파마 피티이. 엘티디. Novel antibodies specific for cthrc1 and use thereof
TWI910146B (en) * 2020-04-14 2026-01-01 法商施維雅藥廠 Anti-flt3 antibodies and compositions

Also Published As

Publication number Publication date
AU2024293963A1 (en) 2026-02-26
WO2025015320A2 (en) 2025-01-16
WO2025015320A3 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
EP3962939A4 (en) Engineered cells expressing anti-tumor t cell receptors and methods of use thereof
EP3635802A4 (en) Materials for electrochemical cells and methods of making and using same
SG11202109589VA (en) T cell receptors and methods of use thereof
ZA202203272B (en) Anti-stem cell factor antibodies and methods of use thereof
SG11202109588RA (en) T cell receptors and methods of use thereof
SG11202109593SA (en) T cell receptors and methods of use thereof
EP3935175A4 (en) T cell receptors and methods of use thereof
GB202019623D0 (en) Electrochemical methods and materials
IL325858A (en) Anti-cthrc1 t cell engagers and methods of using the same
IL315187A (en) Meta cells and an acoustic metametric panel that includes at least one meta acoustic cell
EP4203978A4 (en) Modified b cells and methods of use thereof
IL290228A (en) T cell receptors and methods of use thereof
IL290221A (en) T cell receptors and methods of use thereof
EP3529396A4 (en) Electrochemical cell and method of using same
CA3298347A1 (en) Anti-cthrc1 t cell engagers and methods of using the same
GB202111039D0 (en) Materials and methods
EP3891488A4 (en) Cell scanning technologies and methods of use thereof
SG10201909544YA (en) Genetically Modified T Cells And Uses Thereof
IL289564A (en) Modified cells and related methods
GB2590770B (en) Cell stacks and methods of alignment
GB202211784D0 (en) Methods and uses
GB202101160D0 (en) Materials and methods
SG11202109595TA (en) T cell receptors and methods of use thereof
IL326330A (en) Modified cells and uses thereof
IL316481A (en) Sars-cov-2 antibodies and methods of using the same